
    
      Five parallel treatment groups receiving a 3-dose primary vaccination course: MenC-TT vaccine
      (2 formulations, double-blind) + Infanrix hexa® OR Hib-MenC-TT (2 formulations double-blind)
      + Infanrix penta® OR Meningitec™ + Infanrix hexa® (control). Three blood samples taken,
      before dose 1 and one month after dose 2 and dose 3.
    
  